| DCC0616 |
Amri-59 |
Novel potent inhibitor of peroxiredoxin I (PrxI), increasing cellular ROS, leading to the activation of both mitochondria- and apoptosis signal-regulated kinase-1-mediated signaling pathways |
|
| DCC0617 |
Ams-glu |
Novel small molecule prodrug for use with SEAKER cells, exhibiting enhanced anticancer activity |
|
| DCC0618 |
Amt580-043 |
Novel inhibitor of the replication of a disease-causing polyomavirus in cell culture |
|
| DCC0619 |
Am-ts23 |
DNA polymerase lambda and beta inhibitor |
|
| DCC0620 |
An11251 |
Novel Anti-Wolbachia Agent with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis |
|
| DCC0621 |
An-329/10738021 |
Novel Neuraminidase (NA) inhibitor |
|
| DCC0622 |
An3365 |
Novel potent and selective leucyl-tRNA synthetase inhibitor |
|
| DCC0623 |
An3485 Hydrochloride |
Inhibitor of TLR2-, TLR3-, TLR4- and TLR5-mediated TNF-α, IL-1β and IL-6 |
|
| DCC0624 |
An8799 |
Novel anti-filariasis agent, being effective in killing Brugia malayi, B. pahangi, and Litomosoides sigmodontis worms |
|
| DCC0625 |
Anacolin |
Anticholinergic agent |
|
| DCC0626 |
And-302 |
Novel Potent Anticonvulsant Agent with In Vitro Neuroprotection |
|
| DCC0627 |
Andrographolide Analogue 3a.1 |
Novel anticancer agent against metastatic Castration resistance and neuroendocrine variant prostate cancers (mCRPC/NEPC), exhibiting synergistic anticancer effect in combination with standard therapy docetaxel and cabazitaxel in mCRPC/NEPC, upregulating H |
|
| DCC0628 |
Angiogenesis Agent C-30 |
Novel angiogenesis agent, showing better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells, significantly increasing the angiogenic potential of vascular endothel |
|
| DCC0629 |
Angiotensin Acetate |
Peptide hormone that causes vasoconstriction and an increase in blood pressure |
|
| DCC0630 |
Ank-199 |
Novel inducer of autophagic cell death through regulating PI3 kinase class III/beclin 1/Atg-related proteins in cisplatin-resistant CAR human oral cancer cells |
|
| DCC0631 |
Ankaflavin |
Novel activator of nuclear factor-erythroid-related factor 2 (Nrf-2) |
|
| DCC0632 |
Annh31 |
Novel potent DYRK1A Kinase Inhibitor |
|
| DCC0633 |
Annh75 |
Novel Potent and Selective DYRK1 Kinase Inhibitor |
|
| DCC0634 |
Annonin Vi |
Natural inhibitor of NADH:ubiquinone oxidoreductase |
|
| DCC0635 |
Ansamitocins |
Antimitotic antibiotic with antitumor, antiprotozoal, and antifungal activities |
|
| DCC0636 |
Ant2681 |
Novel Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae |
|
| DCC0637 |
Ant3310 |
Novel Broad-Spectrum Serine β-Lactamase Inhibitor, Strongly Potentiating Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii |
|
| DCC0638 |
Anti-ad Compound L1 |
Novel anti-AD agent, integrating Aβ-interacting and metal-binding fragments in a single molecular framework, exhibiting significant antioxidant activity and metal chelating ability, and also rescuing neuroblastoma N2A cells from Cu -induced Aβ neurotoxici |
|
| DCC0639 |
Anti-ad-23e |
Novel multitarget directed anti-Alzheimer agent, showing an IC 50 value of 0.56 ± 0.02 μM for AChE and an IC 50 value of 1.17 ± 0.09 μM for BuChE |
|
| DCC0640 |
Antiallergic Agent 36 |
Novel highly potent orally bioavailable antiallergic agent, effectively suppressing mast cell degranulation in a dose-dependent manner (IC50, 2.54 nM for RBL-2H3 cells; 48.28 nM for peritoneal mast cells (PMCs)) |
|
| DCC0641 |
Antiangiogenic Agent G5 |
Novel dose-dependent antiangiogenic agent |
|
| DCC0642 |
Antibacterial Additive 2ai |
Analogue of the marine sponge natural product oroidin, suppresses biofilm formation and enhancing control of copper-resistant Xanthomonas euvesicatoria on pepper |
|
| DCC0643 |
Antibiotic Adjuvant P35 |
Novel Potent and Nontoxic Antibiotic Adjuvant |
|
| DCC0644 |
Anticancer Agent-i |
Novel anticancer agent, showing most significant anti-cancer activity against prostate cancer cells with IC50 values of 8.8 µM and 9.5 µM in PC-3 and DU-145 cells, respectively |
|
| DCC0645 |
Anti-cancer Toxin-1 |
Novel covalent anti-cancer toxin, targeting β-tubulin and covalently modifyng Cys239 within the colchicine binding site |
|
